1. |
Anticonvulsant trials not applicable to clinical practice |
|
Inpharma Weekly,
Volume &NA;,
Issue 1109,
1997,
Page 2-2
&NA;,
Preview
|
PDF (1222KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
2. |
Time for a rethink on treatments for stroke? |
|
Inpharma Weekly,
Volume &NA;,
Issue 1109,
1997,
Page 3-4
Wayne Elwood,
Preview
|
PDF (2232KB)
|
|
摘要:
Over the last few years, there has been a much needed movement in clinical practice towards rapid treatment for patients who experience cerebrovascular stroke so that irreversible neurodegeneration and cell death can be reduced. However, effective pharmacological agents for the treatment of patients with stroke still evade researchers and new treatment options are required. Recent initiatives using familiar drugs from other therapeutic areas and the potential of novel agents in the treatment of stroke were discussed at the 10th Congress of the European College of Neuropsychopharmacology [Vienna, Austria; September 1997].
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
3. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1109,
1997,
Page 5-5
&NA;,
Preview
|
PDF (1014KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
4. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1109,
1997,
Page 6-6
&NA;,
Preview
|
PDF (1166KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
5. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1109,
1997,
Page 7-7
&NA;,
Preview
|
PDF (977KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
6. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1109,
1997,
Page 8-8
&NA;,
Preview
|
PDF (1178KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
7. |
A pure antiestrogen may avoid tamoxifen's adverse effects |
|
Inpharma Weekly,
Volume &NA;,
Issue 1109,
1997,
Page 9-10
Robert Carlson,
Preview
|
PDF (2258KB)
|
|
摘要:
Tamoxifen is widely used as an antiestrogen therapy for all stages of estrogen receptor-positive breast cancer, particularly for advanced disease. However, as well as having an antagonist effect at the estrogen receptor, tamoxifen also has a partial agonist effect in some tissues. While this agonist effect may be positive in terms of a patient's bone mineral density and blood lipid profiles, it has also been associated with endometrial cancer and with stimulation of the breast cancer tumour itself. ICI-182780 [‘Faslodex’; Zeneca] is a ‘pure’ antiestrogen agent that exerts its effect without an accompanying stimulation of tumours or other tissue. Preliminary data suggested that ICI-182780 may avoid some of the drawbacks of tamoxifen and find a role as primary, or at least secondary, endocrine treatment for patients with breast cancer.*The latest clinical developments with ICI-182780 were outlined at a Zeneca-sponsored symposium at the 9th European Cancer Conference (ECCO) [Hamburg, Germany; September 1997].
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
8. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1109,
1997,
Page 10-10
&NA;,
Preview
|
PDF (1143KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
9. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1109,
1997,
Page 11-11
&NA;,
Preview
|
PDF (1000KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
10. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1109,
1997,
Page 12-12
&NA;,
Preview
|
PDF (1126KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|